About this Research Topic
Coeliac disease is an autoimmune-related illness caused by environmental, genetic, and immune triggers. Gluten causes a cascade of immune changes leading to an inflammatory response in the intestine that causes numerous health problems in untreated individuals. Immunotherapy for coeliac disease is an attractive strategy for treatment. T cells are a key cell type in disease pathogenesis and therapeutic approaches targeting this immune subset will be crucial to a better treatment. Understanding the triggers and drivers of the immune response induced by gluten will enable the design of new strategies to treat or even prevent the development of coeliac disease in at risk individuals.
Following decades of research into possible coeliac disease therapeutics, there remain many unanswered questions on optimal immune targets to remove the pathogenic T cell response to gluten in coeliac disease patients. Lessons learnt from past and present work should inform the future of the coeliac disease research field and the field of autoimmunity as a whole. Where is the field now? Where should the field be in 5 years’ time? What are the most promising therapeutics and why? Can coeliac disease by prevented in genetic at risk individuals? Lessons learnt from prevention trials? Have we targeted the correct cytokine responses? Have we forgotten about the auto-antigen? Do we need to know more about what gluten is actually doing in the small intestine? Is disease prevention the ultimate goal?
The aim of this Research Topic is to delve into the immune dysfunction in coeliac disease, the possible causes for these immune changes, and how to therapeutically target them. We welcome Mini-Review or Perspective articles addressing specific coeliac disease/autoimmune research field questions and Original Research articles on coeliac disease themes such as:
1. Gluten induced T lymphocyte responses and how to target them
2. Cytokine responses and related interventions
3. Gluten and transglutaminase 2 immune responses
4. Biomarkers for coeliac disease
5. Treatment and prevention of coeliac disease
6. Immune responses in the small intestine
Dr Anderson the owner of Novoviah Pharmaceuticals Pty Ltd, and Novoviah Consulting Pty Ltd and a Honorary Research Fellow at Wesley Medical Research in Brisbane. The other Topic Editors declare no competing interests with regards to the Research Topic.
Keywords: Coeliac disease, lymphocytes, gluten/auto antigen, cytokines, immunotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.